SOYSAL, P., ISIK, A.T., STUBBS, B., SOLMI, M., VOLPE, M., LUCHINI, C., D'ONOFRIO, G., PILOTTO, A., MANZATO, E., SERGI, G., SCHOFIELD, Patricia and VERONESE, N. (2016). Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: A systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 87 (12), 1368-1374.
|
PDF
Schofield-AcetylcholinesteraseInhibitorsAssociated(AM).pdf - Accepted Version Creative Commons Attribution Non-commercial. Download (415kB) | Preview |
Abstract
© 2016 Published by the BMJ Publishing Group Limited. We conducted a systematic review and meta-analysis investigating the influence of acetylcholinesterase inhibitors (AChEIs) therapy on nutritional status and weight across observational and interventional studies. Two authors searched major electronic databases from inception until 10/14/2015 for longitudinal, open-label and randomised double-blind placebo controlled (randomised controlled trials (RCTs)) studies of AChEIs in patients with dementia reporting nutritional status outcome data. Out of 3551 initial hits, 25 studies (12 open-label trials, 9 RCTs and 4 longitudinal studies) including 10 792 patients with dementia were meta-analysed. In longitudinal studies (median follow-up 6 months), a significant cumulative incidence of weight loss between baseline and follow-up evaluation was observed (studies=2; 5%; 95% CI 1% to 34%, p<0.0001; I2 =95%). These findings were confirmed in open-label trials (6%; 95% CI 4% to 7%, p<0.0001; I2 =78%). In 9 RCTs (median follow-up 5 months), those taking AChEIs more frequently experienced weight loss than participants taking placebo (OR=2.18; 95% CI 1.50 to 3.17, p<0.0001; I2 =29%). AChEIs therapy contributes to weight loss in patients with dementia, with a 2-fold increased risk observed in the meta-analysis of RCTs. Clinicians should carefully consider the benefit and risk of prescribing AChEIs. Nutritional status should be routinely evaluated in patients with dementia treated with AChEIs.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | ALZHEIMER'S DISEASE; DEMENTIA; GERIATRICS; META-ANALYSIS; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Female; Humans; Male; Randomized Controlled Trials as Topic; Risk Assessment; Weight Loss; Humans; Alzheimer Disease; Weight Loss; Cholinesterase Inhibitors; Risk Assessment; Aged; Female; Male; Randomized Controlled Trials as Topic; 11 Medical and Health Sciences; 17 Psychology and Cognitive Sciences; Neurology & Neurosurgery |
Identification Number: | https://doi.org/10.1136/jnnp-2016-313660 |
Page Range: | 1368-1374 |
SWORD Depositor: | Symplectic Elements |
Depositing User: | Symplectic Elements |
Date Deposited: | 19 Nov 2020 17:42 |
Last Modified: | 17 Mar 2021 20:16 |
URI: | https://shura.shu.ac.uk/id/eprint/27327 |
Actions (login required)
View Item |
Downloads
Downloads per month over past year